GlassScriptPhysician profile
Imran Shafqat
NPI 1336404540
$1,718.73
in general payments reported to CMS, 2019-2025
28 companies · $191 in 2025
The $191 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $735 · 2020: $282 · 2021: $68.06 · 2022: $144 · 2023: $162 · 2024: $137 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $315 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $314.75 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $320.11 | 2019-2021 | |
| Amgen INC. | $273.12 | 2019-2025 | Prolia, Evenity, Prolia |
| Novo Nordisk INC | $250.30 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Alkermes, INC. | $96.41 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.32 | 2019-2024 | Tradjenta, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.29 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $60.76 | 2019-2024 | Farxiga |
| Glaxosmithkline, LLC. | $54.64 | 2019-2023 | Trelegy Ellipta |
| Pfizer INC. | $50.80 | 2019-2023 | |
| Lilly USA, LLC | $50.27 | 2019-2020 | |
| Abbvie INC. | $49.71 | 2023-2024 | Vraylar |
| Janssen Pharmaceuticals, INC | $43.31 | 2019-2024 | Spravato |
| Merck Sharp & Dohme LLC | $42.59 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Sanofi Pasteur INC. | $36.08 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $32.22 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $28.58 | 2019 | |
| Shire North American Group INC | $23.22 | 2019 | |
| Astellas Pharma US INC | $18.23 | 2019 | |
| Radius Health, INC. | $18.11 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.83 | 2020 | |
| Orexo US, INC. | $16.66 | 2019 | |
| Coopersurgical, INC. | $15.59 | 2019 | |
| Gilead Sciences, INC. | $15.41 | 2020 | |
| Abbott Laboratories | $15.23 | 2024 | Freestyle Libre 3 |
| Phadia US INC. | $13.91 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.79 | 2019 | |
| Ironshore Pharmaceuticals INC. | $12.30 | 2019 | |
| Indivior INC. | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Shafqat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.